Incyte News

Intel Corporation : JPMorgan views Dell's results and guidance as a negative data point for Intel and reiterates a Neutral rating on shares of Intel.

WILMINGTON, Del. -- -- Incyte Corporation announced today it will present at the following investor conferences during the month of June: Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6, 2012 at 3:20 pm / 6:20 pm in Rancho Palos Verdes; The presentations will be webcast live and can be accessed at www.incyte.com under ... (more)

's stock had its "neutral" rating restated by Zacks in a research report issued to clients and investors on Monday.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF where we have detected an approximate $91.0 million dollar inflow - that's a 16.7% increase week over week in outstanding units .

Goldman Sachs has upgraded Incyte from Neutral to Buy with a price target of $29 , suggesting a 26% premium from today's prices as the drug discovery company focused on developing proprietary small molecule drugs has now become the latest M&A target Those that follow Incyte Corporation, know that it has a broad range of discovery capabilities ... (more)

Shares of Incyte opened at 23.02 on Friday. Incyte has a 52 week low of $11.76 and a 52 week high of $23.40. The company's market cap is $2.949 billion.

Do you consider yourself a contrarian? If you look for investing opportunities against the market's trends, your answer might be yes.

YM Biosciences Inc. has stated that it is currently in discussions with the FDA to agree on a protocol for the Phase III clinical trial design for its lead product candidate CYT387, for the treatment of myelofibrosis .

WILMINGTON, Del. -- -- Incyte Corporation announced today it will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 11:20 a.m. / 2:20 p.m. in Las Vegas.